Supernus has boosted its position in central ... are for Parkinson's disease, while the third (Myobloc) is a botulinum toxin product for cervical dystonia and chronic sialorrhea.
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...
Feb 4 (Reuters) - The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' (SUPN.O), opens new tab drug-device combination to treat movement-related symptoms of Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback